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One of the core symptoms in post-
traumatic stress disorder (PTSD) is the
traumatic memory that constantly haunts
the patient. PTSD is a paradoxical disor-
der of memory—on the one hand, intru-
sive recollections for certain aspects of the
event and, on the other hand, amnesia
for other important aspects (Ehlers et al.,
2004). Intrusive memories, often triggered
automatically by situations that reflect
aspects of the traumatic event, are accom-
panied by high levels of arousal and might
be experienced as “flashbacks” (vanOyen
Witvliet, 1997).
A major question in studying PTSD
is how can an external traumatic event
impact on the biology of the organism to
produce such durable memory traces of
that event that are so highly resistant to
extinction? (Pitman, 1989).
An increasing body of evidence points
to the endocannabinoid (eCB) system as a
key system in the regulation of emotional-
ity and memory (Haller et al., 2002, 2004;
Marsicano et al., 2002; Lutz, 2007; Ganon-
Elazar and Akirav, 2009; Abush and
Akirav, 2010; Moreira and Wotjak, 2010;
Parolaro et al., 2010; Atsak et al., 2012b;
Ganon-Elazar and Akirav, 2012, 2013;
Abush and Akirav, 2013; Campolongo
et al., 2013). Hence, eCB enhancers may
be the ideal pharmacological treatment for
PTSD by blocking the pathological over
consolidation and continuous retrieval of
the traumatic event on the one hand,
and enhancing its extinction and reducing
the anxiety symptoms on the other hand.
These effects fit well with the concept of
reducing fear memory.
These ideas were recently published in
an interesting and highly relevant per-
spective by Trezza and Campolongo. The
authors suggested the eCB system as a
possible pharmacological treatment that
modulates the consolidation, retrieval and
extinction of these durable memory traces.
Together with the effects of eCB on stress
and anxiety, the whole PTSD spectrum is
addressed.
The authors reviewed the literature
suggesting that eCBs have an essential
role in maintaining emotional homeosta-
sis (Haller et al., 2002, 2004; Lutz, 2007;
Niyuhire et al., 2007; Hill and Gorzalka,
2009; Moreira and Wotjak, 2010; Parolaro
et al., 2010) and in modulating mem-
ory consolidation, retrieval and extinc-
tion (Marsicano et al., 2002; Niyuhire
et al., 2007; Marsicano and Lafenetre,
2009; Atsak et al., 2012a; Campolongo
et al., 2013). Specifically, cannabinoids
strongly facilitate memory extinction in
animals (Marsicano et al., 2002; Lutz,
2007; Abush and Akirav, 2010), while
impairing memory retrieval (Niyuhire
et al., 2007; Atsak et al., 2012a). Regarding
the effects of cannabinoids on mem-
ory consolidation for emotionally salient
events, they reported controversial results
from preclinical studies. On the one hand,
post-training administration of cannabi-
noid receptor direct or indirect agonists
facilitated memory consolidation in the
inhibitory avoidance task (Campolongo
et al., 2009; Hauer et al., 2011). However,
other studies suggested that cannabinoid
agonists administered to rats shortly after
exposure to a series of intense stress-
ful events prevented PTSD-like symptoms
(Ganon-Elazar and Akirav, 2012, 2013).
Hence, the authors concluded that
eCBs could be an ideal drug to treat PTSD
by addressing both the emotional and cog-
nitive aspects of the disorder. Yet, attention
needs to be dedicated to the time framing
of pharmacological treatment, with an
attempt to avoid the first early phases of
memory consolidation.
Indeed, accumulating data from both
clinical and pre-clinical studies suggest
that targeting the eCB system may ben-
efit PTSD. Given the similarities between
extinction procedures and exposure-based
psychotherapy used for the treatment
of fear disorders in humans (Myers
and Davis, 2007), the eCB system rep-
resents a novel pharmacological target
for anxiety disorders related to inap-
propriate retention of aversive memories
(Marsicano et al., 2002; Chhatwal et al.,
2005; Bitencourt et al., 2008). Accordingly,
human studies suggest that cannabinoids
may be used as an adjunct to extinction-
based therapies for anxiety disorders. In
support, Rabinak et al. (2013) found that
subjects that received 9–THC showed
enhanced extinction memory and Das
et al. (2013) showed a similar effect using
the agonist cannabidiol.
A recent study with rats suggested
that predator exposure causes long-
lasting anxiogenic effects associated with
hyperactivation of amygdaloid com-
plex and modulation of CB1 receptor
in brain areas related to PTSD symp-
toms (Campos et al., 2013). Seven days
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after predator threat rats showed last-
ing anxiogenic effects and CB1 mRNA
expression was down regulated in the
frontal cortex and amygdaloid complex
(Campos et al., 2013). Studies in humans
also suggested alterations in the eCB
system in PTSD. Hauer et al. (2013)
indicated that individuals with PTSD
show significant differences in plasma
concentrations of eCBs and related N-
acyl-ethanolamides when compared to
healthy controls and to subjects after
trauma exposure who did not develop
PTSD. Neumeister et al. (2013) reported
that PTSD patients demonstrated elevated
brain cannabinoid CB1 receptor avail-
ability and suggested that abnormal CB1
receptor-mediated anandamide signaling
is implicated in the etiology of PTSD.
Moreover, it has been suggested that
higher CB1 receptor density in women
than men under basal (i.e., nonstress)
conditions may explain the epidemiologi-
cal literature consistently reporting gender
differences in PTSD. Hence, higher CB1
receptor density in women may be a risk
factor to developing PTSD after trauma
(Neumeister, 2013).
Cannabinoid agonists administered
shortly after exposure to an intense
stressful event (i.e., exposure to 2 h
restraint followed by forced swim and
sedation or exposure to predator stress)
can prevent the development of PTSD-
like symptoms in rats (Campos et al.,
2012; Ganon-Elazar and Akirav, 2012,
2013), suggesting that eCB enhancers
may be beneficial in PTSD. Indeed, two
open label clinical trials demonstrated
potential benefits of cannabis in patients
with PTSD. Fraser (2009) found that
the synthetic cannabinoid nabilone sig-
nificantly improved treatment-resistant
nightmares in PTSD patients. Shalev’s
(Shalev et al., 2013) group reported
that 10 outpatients with chronic PTSD
that received 9–THC twice a day
for 3 weeks demonstrated a significant
improvement in arousal, sleep quality and
nightmares.
Several studies support the self-
medication hypothesis explanation for
cannabis use to cope with PTSD symp-
toms (Cougle et al., 2011; Passie et al.,
2012). Others reported a strong correla-
tion between PTSD symptom severity and
the amount of cannabis use (Bonn-Miller
et al., 2011; Cougle et al., 2011; Potter
et al., 2011). Moreover, the starting point
of using cannabis correlated with the onset
of PTSD symptoms (Cougle et al., 2011)
suggesting that cannabis use was used to
help reduce aversive mood states.
To conclude, the eCB system may be a
useful target for treating both the cogni-
tive and emotional features of PTSD, but
more research is needed in order to rec-
ognize and avoid the circumstances under
which a pharmacological treatment with
eCB agents might have a deleterious effect
on behavior.
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